ECSP088463A - Antagonistas de activina-actriia y usos para promover el crecimiento óseo - Google Patents

Antagonistas de activina-actriia y usos para promover el crecimiento óseo

Info

Publication number
ECSP088463A
ECSP088463A EC2008008463A ECSP088463A ECSP088463A EC SP088463 A ECSP088463 A EC SP088463A EC 2008008463 A EC2008008463 A EC 2008008463A EC SP088463 A ECSP088463 A EC SP088463A EC SP088463 A ECSP088463 A EC SP088463A
Authority
EC
Ecuador
Prior art keywords
actriia
activina
bone growth
promote bone
actriia antagonists
Prior art date
Application number
EC2008008463A
Other languages
English (en)
Spanish (es)
Inventor
John Knopf
Jasbir Seehra
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of ECSP088463A publication Critical patent/ECSP088463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
EC2008008463A 2005-11-23 2008-05-22 Antagonistas de activina-actriia y usos para promover el crecimiento óseo ECSP088463A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73946205P 2005-11-23 2005-11-23
US78332206P 2006-03-17 2006-03-17
US84485506P 2006-09-15 2006-09-15
PCT/US2006/045322 WO2007062188A2 (en) 2005-11-23 2006-11-22 Activin-actriia antagonists and uses for promoting bone growth

Publications (1)

Publication Number Publication Date
ECSP088463A true ECSP088463A (es) 2008-07-30

Family

ID=38067939

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008463A ECSP088463A (es) 2005-11-23 2008-05-22 Antagonistas de activina-actriia y usos para promover el crecimiento óseo

Country Status (24)

Country Link
US (9) US7612041B2 (enExample)
EP (5) EP3811965A1 (enExample)
JP (9) JP5261187B2 (enExample)
KR (8) KR20200041386A (enExample)
CN (4) CN103432568A (enExample)
AU (1) AU2006318449B2 (enExample)
BR (1) BRPI0618947B1 (enExample)
CA (2) CA2631013C (enExample)
CR (1) CR10008A (enExample)
DK (1) DK1973559T3 (enExample)
EA (4) EA201692543A1 (enExample)
EC (1) ECSP088463A (enExample)
ES (3) ES2839549T3 (enExample)
HR (1) HRP20080377B1 (enExample)
IL (5) IL191596A (enExample)
IN (1) IN2015DN02553A (enExample)
ME (1) ME00380B (enExample)
MX (1) MX2008006626A (enExample)
NZ (1) NZ568369A (enExample)
PL (1) PL1973559T3 (enExample)
PT (1) PT1973559E (enExample)
RS (1) RS58231B1 (enExample)
SG (1) SG10201509620SA (enExample)
WO (1) WO2007062188A2 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) * 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2006318449B2 (en) * 2005-11-23 2012-07-05 Acceleron Pharma Inc. Activin-actRIIa antagonists and uses for promoting bone growth
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
EA035911B1 (ru) * 2006-12-18 2020-08-31 Акселерон Фарма Инк. Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства
AU2016250354B2 (en) * 2006-12-18 2019-01-17 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
AU2013221910B2 (en) * 2006-12-18 2016-11-17 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
TR200906131T1 (tr) * 2007-02-01 2009-11-23 Acceleron Pharma Inc. Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CN104548056B (zh) * 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
AU2013204959B2 (en) * 2007-02-09 2016-05-19 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
AU2016202691B2 (en) * 2007-02-09 2018-03-15 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for promoting bone growth in cancer patients
US8318135B2 (en) * 2007-03-19 2012-11-27 National Research Council Of Canada Antagonist of ligands and uses thereof
US7960343B2 (en) * 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
WO2009137075A1 (en) * 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
MX2010012437A (es) 2008-05-14 2011-06-01 Agriculture Victoria Serv Pty Uso de angiogenina o agonistas de angiogenina para tratar enfermedades y trastornos.
PE20091931A1 (es) * 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
KR101871510B1 (ko) * 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
NZ602471A (en) * 2008-06-26 2014-10-31 Acceleron Pharma Inc Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (da) * 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf-fanger til anvendelse ved behandling af anæmi
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
CN102548617B (zh) * 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR20210029836A (ko) * 2009-09-09 2021-03-16 악셀레론 파마 인코포레이티드 ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
CN103917563A (zh) 2011-06-28 2014-07-09 英伊布里克斯有限责任公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
US20140120149A1 (en) * 2012-10-30 2014-05-01 The Royal Institution For The Advancement Of Learning/Mcgill University Calcium sulphate based composite
MX366336B (es) * 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
WO2015143199A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
HK1252174A1 (zh) 2015-05-20 2019-05-17 细胞基因公司 使用II型活化素受体配体阱的用於β-地中海贫血的体外细胞培养方法
ES2967078T3 (es) 2015-09-23 2024-04-25 Bristol Myers Squibb Co Dominios de fibronectina de tipo III de unión a seroalbúmina con velocidad de disociación rápida
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
MX378869B (es) 2016-07-15 2025-03-10 Acceleron Pharma Inc Composiciones y metodos para tratar hipertension pulmonar.
WO2018022762A1 (en) 2016-07-27 2018-02-01 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
CN110198743B (zh) 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
CN119591692A (zh) 2016-11-10 2025-03-11 科乐斯疗法公司 激活素受体iia型变体及其使用方法
PT3600415T (pt) 2017-03-24 2025-11-24 Novartis Ag Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN109320597B (zh) * 2018-10-26 2021-10-26 中国农业科学院特产研究所 狐亚科激活素a蛋白及其制备与应用
AU2020356575A1 (en) 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CN115768457A (zh) 2020-03-20 2023-03-07 科乐斯疗法公司 激活素受体ii型嵌合体以及其使用方法
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL297627A (en) * 2020-04-28 2022-12-01 Acceleron Pharma Inc actrii proteins and their use in the treatment of postcapillary pulmonary hypertension
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CN114594170B (zh) * 2020-12-03 2024-05-17 复旦大学 一种磁固相萃取结合快速原位衍生化的体内药物分析方法
WO2022261437A2 (en) * 2021-06-11 2022-12-15 Acceleron Pharma Inc. Actrii proteins and uses thereof
EP4469489A1 (en) 2022-01-28 2024-12-04 35Pharma Inc. Activin receptor type iib variants and uses thereof
CR20250375A (es) * 2023-03-09 2025-10-07 Merck Sharp & Dohme Llc Formulaciones que comprenden variantes de la proteína actriia
AU2024231427A1 (en) * 2023-03-09 2025-09-04 Merck Sharp & Dohme Llc Formulations comprising actriia polypeptide variants
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1992004913A1 (en) 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
KR100255415B1 (ko) 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
WO1993020207A1 (en) * 1992-04-02 1993-10-14 The United States Of America, As Represented By The Secretary Of Health And Human Services Use of restriction endonucleases against viruses, including hiv
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0679163A4 (en) 1993-01-12 1997-07-16 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-3.
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) * 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
CA2187902A1 (en) * 1994-04-29 1995-11-09 Peter Ten Dijke Morphogenic protein-specific cell surface receptors and uses therefor
IL114397A0 (en) * 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
US6132988A (en) * 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
BR9712675A (pt) 1996-10-25 1999-10-19 Searle & Co Agonistas do receptor de eritropoietina circularmente permutados.
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
DE69840361D1 (de) 1997-07-30 2009-01-29 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
BR9812846A (pt) 1997-10-03 2000-08-08 Chugai Pharmaceutical Co Ltd Anticorpo humanizado natural
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
CA2330939A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
JP2002524514A (ja) * 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
CA2343715C (en) 1998-09-22 2004-05-18 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DK2261335T3 (en) * 1998-11-27 2017-09-18 Ucb Pharma Sa Compositions and Methods for Increasing Bone Mineralization
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
HRP20020387A2 (en) 1999-11-12 2005-10-31 Maxygen Holdings Ltd. Interferon gamma conjugates
DE60026592T2 (de) 1999-12-15 2006-12-14 Research Development Foundation, Carson City Betaglycan als ein inhibin rezeptor und dessen verwendung
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
CZ304855B6 (cs) 2000-05-15 2014-12-10 F. Hoffmann-La Roche Ag Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US20030215913A1 (en) 2000-07-19 2003-11-20 Enrique Alvarez Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
AU2567002A (en) 2000-11-20 2002-05-27 Univ Illinois Membrane scaffold proteins
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US20040132971A1 (en) * 2001-02-09 2004-07-08 Haaning Jesper Mortensen Rank ligand-binding polypeptides
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
WO2002074340A1 (fr) 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
JP2004535182A (ja) 2001-05-24 2004-11-25 ザイモジェネティクス，インコーポレイティド Ｔａｃｉ−免疫グロブリン融合タンパク質
CA2448253A1 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
CA2452246A1 (en) 2001-07-17 2003-01-30 Teijin Limited Method of screening substance by measuring ppar .delta. activating effect and agent
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
CA2467689C (en) 2001-12-06 2013-10-01 Fibrogen, Inc. Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
US8053552B2 (en) * 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
MXPA05001694A (es) 2002-08-16 2005-07-22 Wyeth Corp Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos.
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
NZ541593A (en) 2003-02-07 2009-05-31 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
BRPI0410927A (pt) 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
NO345763B1 (no) 2003-06-16 2021-07-19 Celltech R&D Inc Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
AU2005229072A1 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. BMP-3 propeptides and related methods
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
CA2572330A1 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. Gdf3 propeptides and related methods
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8617815B2 (en) 2004-08-05 2013-12-31 The Regents Of The University Of California Molecules with effects on cellular development and function
BRPI0514253A (pt) 2004-08-12 2008-06-03 Wyeth Corp terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
WO2006039400A2 (en) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
NL1027887C2 (nl) 2004-12-24 2006-06-27 Bosch Gmbh Robert Transmissie met gebombeerde poelieschijven en een drijfriem.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
EA015534B1 (ru) 2005-04-25 2011-08-30 Пфайзер Инк. Антитела к миостатину и способы их применения
WO2006115274A1 (ja) 2005-04-26 2006-11-02 Ajinomoto Co., Inc. 骨髄赤血球前駆細胞分化促進剤
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
PT1931697E (pt) 2005-09-28 2010-12-06 Zymogenetics Inc Antagonistas de il-17a e il-17f e processos para a sua utilização
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
AU2006318449B2 (en) 2005-11-23 2012-07-05 Acceleron Pharma Inc. Activin-actRIIa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
WO2007071023A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
BRPI0620255A2 (pt) 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
EP1976541B1 (en) 2006-01-20 2011-07-13 Beckman Coulter, Inc. Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
KR20080098615A (ko) 2006-02-28 2008-11-11 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
EP2007813A2 (en) 2006-04-14 2008-12-31 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
WO2007133653A2 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
TW200803123A (en) * 2006-06-02 2008-01-01 Delta Electronics Inc Power converter and magnetic structure thereof
WO2008011126A2 (en) 2006-07-21 2008-01-24 Lyne Laboratories Liquid compositions of calcium acetate
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EA035911B1 (ru) * 2006-12-18 2020-08-31 Акселерон Фарма Инк. Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства
TR200906131T1 (tr) * 2007-02-01 2009-11-23 Acceleron Pharma Inc. Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CN104548056B (zh) * 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US20090017019A1 (en) 2007-06-01 2009-01-15 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
US20090025308A1 (en) * 2007-07-26 2009-01-29 Deans Brian W Seismic support and reinforcement systems
PE20090510A1 (es) 2007-08-03 2009-05-22 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
WO2009035629A1 (en) 2007-09-13 2009-03-19 Ludwig Institute Of Cancer Research Method for modifying cellular immune response by modulating activin activity
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EA201000844A1 (ru) 2007-11-21 2011-10-31 Амген Инк. Связывающие wise агенты и эпитопы
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2011523357A (ja) 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
WO2009137075A1 (en) * 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
KR101871510B1 (ko) 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
NZ602471A (en) 2008-06-26 2014-10-31 Acceleron Pharma Inc Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (da) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf-fanger til anvendelse ved behandling af anæmi
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
UA107921C2 (en) 2008-11-26 2015-03-10 Amgen Inc Variants of polypeptide of receptor ivr activin and their use
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP3838919A1 (en) 2009-08-13 2021-06-23 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
KR20210029836A (ko) 2009-09-09 2021-03-16 악셀레론 파마 인코포레이티드 ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
ES2741477T3 (es) 2011-10-17 2020-02-11 Acceleron Pharma Inc Composiciones para tratar la sobrecarga de hierro en talasemia
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
WO2013059876A1 (en) 2011-10-28 2013-05-02 Paranta Biosciences Limited A method of treating mucus hypersecretion
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9663569B2 (en) 2012-06-14 2017-05-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
CN104411720B (zh) 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
NZ747350A (en) 2012-10-24 2020-07-31 Celgene Corp Methods for treating anemia
JP6401171B2 (ja) 2012-10-24 2018-10-03 セルジーン コーポレイション 貧血の治療に使用するためのバイオマーカー
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
KR102467714B1 (ko) 2012-11-08 2022-11-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
HK1219280A1 (zh) 2013-08-14 2017-03-31 Novartis Ag 治疗偶发性包涵体肌炎之方法
WO2015089575A1 (en) 2013-12-16 2015-06-25 Paranta Biosciences Limited Method of diagnosis and treatment
WO2015108972A1 (en) 2014-01-14 2015-07-23 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CA2950754C (en) 2014-06-04 2021-10-26 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
BR112016029211A2 (pt) 2014-06-13 2018-01-30 Amgen Inc composição, método para inibir um crescimento tumoral sólido em um indivíduo, método para produzir uma proteína, método para inibir, reduzir ou tratar de caquexia em um indivíduo, método para tratar obesidade ou uma doença associada à obesidade e kit
TWI762444B (zh) 2015-05-13 2022-05-01 美商西建公司 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血

Also Published As

Publication number Publication date
JP2016026212A (ja) 2016-02-12
HK1248598A1 (en) 2018-10-19
EP3811965A1 (en) 2021-04-28
BRPI0618947B1 (pt) 2022-07-19
MX2008006626A (es) 2008-09-24
IL191596A (en) 2014-02-27
WO2007062188A3 (en) 2007-09-13
IL230646A0 (en) 2014-03-31
EP3269381B1 (en) 2020-10-07
IL259893B (en) 2021-03-25
US20240358793A1 (en) 2024-10-31
IL191596A0 (en) 2008-12-29
JP2013153765A (ja) 2013-08-15
HRP20080377B1 (hr) 2015-03-27
CN103479994A (zh) 2014-01-01
RS58231B1 (sr) 2019-03-29
IN2015DN02553A (enExample) 2015-09-11
IL259893A (en) 2018-07-31
AU2006318449B2 (en) 2012-07-05
US20140079700A1 (en) 2014-03-20
KR20180030264A (ko) 2018-03-21
EA015105B1 (ru) 2011-06-30
ES2839549T3 (es) 2021-07-05
JP2012125259A (ja) 2012-07-05
MEP59208A (en) 2011-05-10
US20090099086A1 (en) 2009-04-16
EA200801406A1 (ru) 2009-12-30
IL280877A (en) 2021-04-29
ES2401805T3 (es) 2013-04-24
CA3045808A1 (en) 2007-05-31
US20090098113A1 (en) 2009-04-16
EP3269381A1 (en) 2018-01-17
JP2009517051A (ja) 2009-04-30
US7612041B2 (en) 2009-11-03
IL230645A0 (en) 2014-03-31
PT1973559E (pt) 2013-02-19
EP2781222B1 (en) 2017-08-02
JP5785129B2 (ja) 2015-09-24
US10071135B2 (en) 2018-09-11
CN104844713B (zh) 2021-05-14
KR20150115961A (ko) 2015-10-14
KR20190097310A (ko) 2019-08-20
WO2007062188A2 (en) 2007-05-31
JP2019156848A (ja) 2019-09-19
EA201100158A1 (ru) 2011-08-30
US20190192625A1 (en) 2019-06-27
US8629109B2 (en) 2014-01-14
KR101557375B1 (ko) 2015-10-08
EP1973559A2 (en) 2008-10-01
KR20080087092A (ko) 2008-09-30
KR20200041386A (ko) 2020-04-21
US20160120939A1 (en) 2016-05-05
US8067360B2 (en) 2011-11-29
EP1973559B1 (en) 2013-01-09
CR10008A (es) 2008-10-03
JP2018000205A (ja) 2018-01-11
US7951771B2 (en) 2011-05-31
CN104844713A (zh) 2015-08-19
HRP20080377A2 (en) 2008-11-30
EP2329837B1 (en) 2014-04-30
CA2631013A1 (en) 2007-05-31
ME00380B (me) 2011-10-10
US9163075B2 (en) 2015-10-20
KR20160137665A (ko) 2016-11-30
CN103432568A (zh) 2013-12-11
HK1158548A1 (en) 2012-07-20
ES2649983T3 (es) 2018-01-16
KR20190006086A (ko) 2019-01-16
US11129873B2 (en) 2021-09-28
PL1973559T3 (pl) 2013-06-28
IL230645A (en) 2015-10-29
HK1123215A1 (en) 2009-06-12
AU2006318449A1 (en) 2007-05-31
SG10201509620SA (en) 2015-12-30
JP2010094129A (ja) 2010-04-30
KR101585623B1 (ko) 2016-01-19
EA201300330A1 (ru) 2013-11-29
CN105001320A (zh) 2015-10-28
US20220211806A1 (en) 2022-07-07
BRPI0618947A2 (pt) 2011-09-13
KR20130120557A (ko) 2013-11-04
US20120058115A1 (en) 2012-03-08
JP2021151266A (ja) 2021-09-30
JP5261187B2 (ja) 2013-08-14
RS20080336A (en) 2009-07-15
JP2016041733A (ja) 2016-03-31
EA018450B1 (ru) 2013-08-30
CA2631013C (en) 2019-06-11
EP2781222A1 (en) 2014-09-24
CN103479994B (zh) 2019-08-30
US20070249022A1 (en) 2007-10-25
NZ568369A (en) 2011-10-28
EP2329837A1 (en) 2011-06-08
JP6195885B2 (ja) 2017-09-13
CA3045808C (en) 2022-08-16
EA026874B1 (ru) 2017-05-31
DK1973559T3 (da) 2013-03-25
EA201692543A1 (ru) 2017-08-31
IL230646B (en) 2019-10-31

Similar Documents

Publication Publication Date Title
ECSP088463A (es) Antagonistas de activina-actriia y usos para promover el crecimiento óseo
AR061348A1 (es) Preparados estables de laquinimod
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
ME01942B (me) Jedinjenja, preparati i metode
EA200800160A1 (ru) Композиты восстановленной ионной жидкостью целлюлозы в качестве матриц твёрдых подложек
TW200806317A (en) Methods for reducing protein aggregation
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
TW200716646A (en) (S)-N-methylnaltrexone
WO2008098212A3 (en) Extended release formulations of glucagon and other peptides and proteins
NO20090305L (no) Cyklosporin formuleringer
DE602005026031D1 (de) Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
IL196674A (en) Exandin fusion proteins, medicinal preparations containing them, and their use in drug preparation
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
UY31123A1 (es) Proteinas de fusion natriureticas
CL2008003366A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados, inhibidores de proteinas quinasas mek y mapk/erk; proceso de preparacion de los compuestos; composicion farmaceutica que los comprende; conjunto que los comprende; y su uso en la preparacion de medicamentos para el tratamiento de trastornos hiperproliferativos.
ECSP088555A (es) Composiciones farmacéuticas
FR2904316B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
MX2020006822A (es) Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2008094945A3 (en) Compounds and methods for modulating protein expression
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
CY1110040T1 (el) Παραγωγα μεξοτρεξατης που δεσμευουν πρωτεϊνες και φαρμακευτικα μεσα που τα περιεχουν